Unicycive Therapeutics (NASDAQ: UNCY) has announced that the U.S. Patent and Trademark Office has issued a patent for UNI-494 to treat chronic kidney disease (CKD).
According to Unicycive, the patent follows the issuance of an earlier method of use patent for the treatment of acute kidney injury with UNI-494.
Shalabh Gupta, MD, CEO of Unicycive, commented, “While we are focused on seeking FDA approval of our lead product oxylanthanum carbonate, we are pleased to announce the issuance of another patent for our second investigational drug, UNI-494. This patent is part of a broader intellectual property portfolio for UNI-494, which supports potential partnership opportunities and future development efforts. We have completed a Phase I clinical study in healthy volunteers and have received Orphan Drug Designation for the prevention of delayed graft function in patients undergoing kidney transplantation.”
